Pipeline

Programs

Athos Therapeutics is a clinical stage company with assets in Inflammatory Bowel Diseases, lupus, and cancer. Athos is also pursuing discovery efforts against a range of validated and novel drug targets for patients with different autoimmune diseases.

Disease / Indication

Small Molecule

Discovery

Preclinical

Phase 1

Lead Programs

IBD, Lupus & Cancer

ATH-063

Acute Myeloid Leukemia

ATH-272

Atopic Dermatitis & CD

ATH-293

Early Stage Programs

Cancer

ATH-261

IBD, SLE & Sjogren’s

ATH-131

Fibrosis (IPS), MM

ATH-301

IBD, RA

ATH-501

AD, IBD, EoE

ATH-601

IBD: Inflammatory Bowel Diseases

SLE: Systemic Lupus Erythematosus

CD: Celiac Disease

AD: Atopic Dermatitis

RA: Rheumatoid Arthritis

AML: Acute Myeloid Leukemia